Q32 Bio Reports Positive Phase 2a Data for Bempikibart in Alopecia Areata, Plans Registrational Trial in 2027
QTTB has more than doubled off its 52-week low of $1.54 on elevated volume (4.4× avg).
Summary
Q32 Bio announced positive Phase 2a data for bempikibart in alopecia areata, showing meaningful efficacy and a clean safety profile. The company plans to advance into a registrational trial in 2027 and has paid off its remaining debt.
Key Events · Product Development and Regulatory · QTTB
-
Positive Phase 2a Topline Data
Bempikibart achieved a 35.3% mean reduction in SALT score from baseline in the mITT analysis, with 40.0% of patients reaching SALT-20 response at Week 36. Efficacy was seen in both severe and very severe patients, including those with prior JAK inhibitor exposure.
-
Clean Safety Profile
No serious adverse events or Grade 3+ treatment-related events were observed. The most common side effect was mild injection site reactions (36.3% of patients), all resolving without intervention.
-
Registrational Trial Planned for 2027
Q32 Bio intends to advance bempikibart into a registration-directed program in the first half of 2027, with full Part B results to be presented at a future medical meeting.
-
Debt Payoff Strengthens Balance Sheet
On June 24, 2026, the company paid off the remaining $6.8 million under its loan agreement with Silicon Valley Bank, terminating the facility and removing a financial overhang.
Analysis · QTTB · Life Sciences
The 36-week topline results from the SIGNAL-AA Part B trial show clinically meaningful efficacy for bempikibart in severe alopecia areata, with a 35.3% mean reduction in SALT score and 40% of patients achieving SALT-20 response. The drug demonstrated a clean safety profile with no serious adverse events. These results de-risk the program and support advancement into a registration-directed trial in the first half of 2027, a major value inflection point for this $265M market cap biotech. The company also paid off its remaining $6.8M debt, strengthening its balance sheet ahead of pivotal development.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 39.8% of the 397 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTTB was trading at $18.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.5M. The 52-week trading range was $1.54 to $15.02. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.